Despite political and economic challenges, Merck CEO Robert Davis remains optimistic about the company’s ophthalmology business. The recent acquisition of EyeBio brought a $1.3 billion boost, focusing on the trispecific antibody Restoret for diabetic macular edema (DME) and neovascular age-related macular degeneration (AMD). The Phase IIb/III trial for Restoret in DME, known as BRUNELLO, commenced […]
Tag: antibody
Robust Chronic Kidney Disease Pipeline: 75+ Key Pharma Companies Actively
Ziltivekimab, a proprietary anti-interleukin-6 ligand monoclonal antibody, targets residual inflammatory cardiovascular risk in advanced chronic kidney disease (CKD) patients. Developed as a therapy to reduce major cardiovascular adverse events in CKD patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients with moderate to severe CKD, ASCVD, and inflammation face high cardiovascular event risks with no […]
Innovations in Cancer Therapeutics at ASCO Conference
The Summit Therapeutics study on PD1-VEGF antibody ivonescimab showcased promising results in delaying lung cancer progression among patients. This achievement aligns with prior findings and marks a significant milestone in Phase 3 clinical trials, highlighting advancements in cancer treatment. As the ASCO conference unfolds, these developments underscore the ongoing efforts to combat cancer globally, offering […]
Innovative ANGPTL3-Targeting Therapies for High Cholesterol
Exciting developments in the biotech industry are paving the way for new treatments targeting high cholesterol. Recent studies presented at the American College of Cardiology Scientific Session have shown promising results for ANGPTL3-targeting drugs developed by Eli Lilly and Jiangsu Hengrui Pharmaceuticals. Eli Lilly’s solbinsiran, a small interfering RNA therapy, demonstrated significant reductions in apolipoprotein […]
Innovative Tri-Specific Antibodies for Cancer Immunotherapy
Purple Biotech announces their novel CAPTN-3 tri-specific antibody platform at EACR 2025. The company focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, a humanized monoclonal antibody that blocks CEACAM1 to target multiple cancer indications. NT219, a dual inhibitor small molecule, demonstrated anti-tumor activity in a […]
Cancer Bispecific Antibody Collaboration Accelerates Market Entry
The collaboration between BMS and BioNTech, valued up to $11B, aims to expedite BNT327’s market launch and mitigate risks in various settings. This partnership provides BNTX with non-dilutive capital, fortifying its oncology pipeline. Despite modest overall survival hazard ratios compared to progression-free survival, this deal affirms the asset’s value and enhances BNTX’s financial standing for […]
Aquaporin-4 Antibody Titers Influence Neuromyelitis Optica Relapse
In a groundbreaking study on 171 NMOSD patients, researchers found that a decrease in Aquaporin-4 antibody titers led to a significant reduction in relapse rates. Specifically, 25.7% of patients became AQP4-IgG seronegative, resulting in a remarkable decrease in annualized relapse rate. The decline in AQP4-IgG levels was identified as a protective factor against relapse, highlighting […]
